GlassScriptPhysician profile
Anant Jeet
NPI 1790759900
$23,678.26
in general payments reported to CMS, 2019-2025
57 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,568 · 2020: $3,320 · 2021: $3,786 · 2022: $5,136 · 2023: $2,495 · 2024: $2,688 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Consulting Fee: $2,970 · Travel and Lodging: $1,652 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.46 |
| Consulting Fee | $2,970.00 |
| Travel and Lodging | $1,652.21 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,469.04 | 2021-2024 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Abbott Laboratories | $2,725.80 | 2020-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $2,458.75 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,861.99 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,308.70 | 2019-2025 | Afrezza |
| Amgen INC. | $1,276.59 | 2019-2024 | Tepezza, Repatha, Prolia |
| Xeris Pharmaceuticals, INC. | $1,028.75 | 2020-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $983.75 | 2019-2023 | Mounjaro, Humulin, Jardiance |
| Astrazeneca Pharmaceuticals LP | $859.19 | 2019-2022 | |
| Abbvie INC. | $773.06 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $686.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.77 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $504.64 | 2019-2021 | |
| Dexcom, INC. | $458.40 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $445.44 | 2019-2023 | Korlym |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anant Jeet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.